DFTX
Definium Therapeutics, Inc. trades as DFTX and has a market capitalization of $5.21 B, making it the #1389 largest US-listed company by market value. This page tracks Definium Therapeutics, Inc. through 445 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-09
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Major company event | 8-K | 2026-05-19 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| Major company event | 8-K | 2026-05-12 |
| Quarterly report | 10-Q | 2026-05-07 |
| Major company event | 8-K | 2026-05-07 |
| Proxy materials | DEFA14A | 2026-04-27 |
| Proxy statement | DEF 14A | 2026-04-27 |
| Major company event | 8-K | 2026-04-22 |
The largest companies sharing Definium Therapeutics, Inc.'s SEC industry classification (medicinal chemicals & botanical products).
Definium Therapeutics, Inc. (DFTX) has a market capitalization of $5.21 B as of 2026-07-09, ranking #1389 among US-listed companies.
In its latest fiscal year Definium Therapeutics, Inc. reported a net loss of $183.79M.